logo-loader
BioPorto

BioPorto Diagnostics A/S looks for FDA approval for its kidney diagnostic test

BioPorto Diagnostics A/S (CPH:BIOPOR) CEO Peter Eriksen joins Proactive Investors at the 11th Annual Biotech Showcase in San Francisco.

The Copenhagen, Denmark based in-vitro diagnostics company provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. Its product portfolio includes assays for underserved disease states such as NGAL for acute kidney injury.

Quick facts: BioPorto

Price: £0.00

Market: NASDAQ OMX
Market Cap: £0.00
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of BioPorto named herein, including the promotion by the Company of BioPorto in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

'May only be a matter of time' before Uranium price recovery with...

Mining Capital's Alastair Ford discusses the planned slow down in production from Kazatomprom (LON:KAP). The miner's looking to cut output from its Kazakh mines by around 20% through to 2021. He says that extends the timeframe of its previous production curtailment by a further year, and...

3 days ago

2 min read